Advanced ovarian carcinoma
Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma
... with advanced ovarian cancer should be treated by radical debulking surgery aiming at complete tumor ...with advanced disease, when optimal debulking can not be obtained, and therefore these patients ...
8
Case Report Polypoid endometriosis of the ovary mimicking advanced ovarian carcinoma with extensive peritoneal metastases
... bilateral ovarian masses, a highly elevated serum CA-125 level, ascites, peritoneal dissemination, and rectosigmoid ...to advanced ovarian carcinoma with extensive peritoneal ...
6
How to improve the optimal cytoreductive surgery in advanced ovarian carcinoma
... Abstract Advanced ovarian carcinoma is a lethal tumour, and its standard treatment is consists of aggressive primary cytoreductive surgery followed by a chemoadjuvance based on platinum ...the ...
10
Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma
... paclitaxel chemotherapy in advanced ovarian carcinoma, over 75% of patients with stage III/IV disease ultimately relapse and die from their disease. Treatment after relapse is dependent upon initial ...
9
Effect of Neoadjuvant Chemotherapy in Advanced Ovarian Carcinoma
... Neoadjuvant Chemotherapy was originally introduced in the year 1969 for patients with advanced stage ovarian cancer and were medically disabled. Over the ensuing decade reasonable experience was obtained ...
98
Clinical and surgical outcomes of 3 cycles versus 6 cycles of neoadjuvant chemotherapy in advanced ovarian carcinoma
... common ovarian malignancy accounting for 90% of all type of ovarian ...have advanced stage III or IV carcinoma ovary at the time of diagnosis as it has vague and nonspecific symptoms in early ...
5
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Advanced Ovarian Carcinoma: Initial Experience in Mexico
... treatment is available for recurrent disease. Based on their response to previous platinum therapy after first-line treatment, patients are categorized into the following groups: platinum-sensitive, with a ...
5
Update on first-line treatment of advanced ovarian carcinoma
... When considering who should receive bevacizumab, the greatest benefit seems to be in those at greatest risk of recurrence, perhaps because the requirement for an additional blood supply is greater in larger tumors than ...
7
Mini-laparotomy in advanced ovarian cancer
... Abstract Optimal cytoreduction (OCR) remains the gold standard treatment of ovarian cancer. Current radiological imaging has limited sensitivity and specificity in prediction of achieving OCR prior to surgery. ...
5
Dose optimization of oral targeted therapies in oncology
... (2005) Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a pha[r] ...
92
Original Article Expression of Talin1 in tissues of ovarian cancer and its role in invasion and migration of ovarian cancer cells
... The proteins were extracted from different ovarian cancer cells, and the protein concen- trations were determined by BCA method, and then loading buffer was added for protein dena- turation. 8% and 10% SDS-PAGE ...
8
Pathological features, clinical presentations and prognostic factors of ovarian large cell neuroendocrine carcinoma: a case report and review of published literature
... of ovarian high- grade serous ...neuroendocrine ovarian tumors, the optimal treatment should be used against the epithelial component, such as first-line che- motherapeutic regimens of paclitaxel plus ...
11
Germline SMARCA4 mutations in patients with ovarian small cell carcinoma of hypercalcemic type
... Until recently, the SCCHT remained a mystery in terms of histogenesis and molecular background [2,8-10]. In year 2013, our research group has described its development in association with an ovarian immature ...
6
MiR-23b targets cyclin G1 and suppresses ovarian cancer tumorigenesis and progression
... In this study, we also found that miR-23b overexpres- sion downregulated uPA expression, which is in line with the findings of Salvi et al. [15], who reported that miR-23b overexpression leads to uPA downregulation and ...
10
Establishment of a new representative model of human ovarian cancer in mice
... the ovarian cancer spread process: It helps tumor cells penetrate the basement membrane of the ovary to in- vade the stroma [21], and may enable the tumor cells to detach from the epithelial surface and migrate ...
7
Download Download PDF
... Ovarian cancer is the most common gynecological malignancy, with over 5,000 new cases diagnosed every year in the UK and 22,000 in United States. Malignant neoplasm of the ovaries occur at all ages and the ...
5
High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the “SET” feature of high-grade serous carcinoma to the “STEM” feature
... major ovarian carcinomas ...mucinous carcinoma was estimated to ap- proximately 0.2% of the total ovarian epithelial carcin- omas, according to their ...
6
<p>Parity as a Prognostic Factor in Patients with Advanced-Stage Epithelial Ovarian Cancer</p>
... with ovarian cancer in the south of Iran, from January 1, 2001, to December 31, 2016, were retrospectively ...epithelial ovarian cancer, with tumors with an ...
10
Prediction of the response to chemotherapy in ovarian cancers
... Metallothioneins (MTs) are low molecular weight proteins (6–7 kDa) whose chains are com- posed of 61 or 62 amino acids. Typically, they con- tain multiple cysteine residues and few aromatic amino acids. MTs are thought ...
10
Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling
... in ovarian cancer patient samples was analyzed to define potential therapeutic ...in ovarian cancer cell lines confirmed the activation of ...of ovarian cancer cells with T-DM1 provoked the ...
15